Mixed Smallpox Vaccine Stockpile Could Complicate Mass Vaccination, Bavarian Nordic Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Smallpox vaccine candidate Imvamune has not demonstrated the potential for serious adverse events associated with Wyeth's Dryvax or Acambis/Baxter's ACAM-2000, VP-R&D Paul Chaplin, PhD, says in interview with "The Blue Sheet."
You may also be interested in...
Bavarian Nordic, GSK To Produce Imvamune For Smallpox Vaccine Stockpile
The companies will collaborate on manufacturing the modified vaccinia Ankara-Bavarian Nordic vaccine for any future HHS contracts. Under the deal, GSK will also market Imvamune in the Americas, Japan and parts of the EU.
Bavarian Nordic, GSK To Produce Imvamune For Smallpox Vaccine Stockpile
The companies will collaborate on manufacturing the modified vaccinia Ankara-Bavarian Nordic vaccine for any future HHS contracts. Under the deal, GSK will also market Imvamune in the Americas, Japan and parts of the EU.
Bavarian Nordic Smallpox Vaccine Is Imvamune; U.S. Trials To Commence This Year
The company expects to begin large-scale production by mid-2005 and plans to seek a U.S. commercialization partner for the third-generation smallpox vaccine.